Skip to content
Clinical Trials – home

Hospital Hm Nou Delfos

Research site

Spain Avinguda De Vallcarca 151, 08023 Barcelona, Spain

  • 24 trials recruiting
  • Neoplasm · Neoplasm malignant · Non-small cell lung cancer
  • Adults and children

About Specializations

Hospital Hm Nou Delfos in Barcelona, Spain specialises in clinical trials of conditions such as Neoplasm, Neoplasm malignant, Non-small cell lung cancer, Breast cancer, and other specialisations. This site conducts important research.

Main research areas of the site

Musculoskeletal Diseases

Research at Hospital Hm Nou Delfos focuses on musculoskeletal conditions, aiming to improve pain management and functional outcomes.

  • Knee osteoarthritis pain
  • Diabetic peripheral neuropathic pain

These studies test therapeutic agents designed to reduce discomfort and enhance mobility for patients with joint and nerve‑related pain.

Neoplasms

The oncology department conducts extensive investigations into cancers, seeking safer and more effective treatments.

  • Advanced solid tumors with KRASG12C mutation
  • HER2‑positive breast and lung cancers
  • Head and neck squamous cell carcinoma
  • Metastatic solid malignancies

Trials evaluate novel antibodies, targeted inhibitors, and combination regimens to halt tumor growth and improve survival rates.

Nervous System Diseases

Studies at the site also address disorders of the nervous system, concentrating on chronic pain syndromes linked to nerve damage.

  • Diabetic peripheral neuropathic pain
  • Neuropathic pain in solid tumor patients
  • Head and neck squamous cell carcinoma with neurological involvement

The goal is to assess safety and efficacy of emerging analgesic compounds, offering hope for better quality of life.

Clinical Trials Concierge

Prefer not to search? Our Concierge searches the trials for you.

Site location
Avinguda De Vallcarca 15108023 BarcelonaSpain
Recruiting now
24 trials
Conditions studied
49

More sites in BarcelonaSpain

Recruiting now

Ongoing trials

Clinical trials currently enrolling participants at this site.

Condition
Type of trial
Recruitment status
Quick filters

52 clinical trials

Study on the Safety and Effectiveness of GSK5733584 with Dostarlimab and Carboplatin for Patients with Advanced Gynecological Tumors

Registered drugNo placebo
Countries:SpainSpain
  • Participants:18–64 years · 65+ years
  • Substances:Bevacizumab
  • Sponsor:Glaxosmithkline Research & Development Limited

Neoplasm

Recruiting

Safety and Tolerability of AZD4956 Alone or with Saruparib in Adults with Advanced Metastatic Solid Tumors (Phase I/IIa)

InvestigationalNo placebo
Countries:SpainSpain
  • Participants:18–64 years · 65+ years
  • Substances:Saruparib
  • Sponsor:AstraZeneca AB

Neoplasm

Recruiting

Phase 1/2 Study of ter-2013-01, imlunestrant, and fulvestrant in patients with solid tumors with AKT/PI3K/PTEN pathway alterations

Registered drugNo placebo
Countries:SpainSpain
  • Participants:18–64 years · 65+ years
  • Substances:Fulvestrant

Safety and Tolerability of Alisertib Sodium and Paclitaxel in Patients with Small Cell Lung Cancer (Phase 2 Study)

Registered drugNo placebo
Countries:SpainSpain
  • Participants:18–64 years · 65+ years
  • Substances:Alisertib Sodium
  • Sponsor:Puma Biotechnology Inc.

Neoplasm+1

Recruiting

Safety and Tolerability of Inhaled KB707 with or without Docetaxel in Patients with Advanced Lung Solid Tumors

Registered drugNo placebo
Countries:SpainSpain
  • Participants:18–64 years · 65+ years
  • Substances:Docetaxel

Colorectal cancer+2

Recruiting

Study of RMC-6291 with ivonescimab drug combination in patients with advanced RAS‑mutated solid tumors

Registered drugNo placebo
Countries:SpainSpain
  • Participants:18–64 years · 65+ years
  • Substances:Carboplatin
  • Sponsor:Revolution Medicines Inc.

Endometrial cancer+8

Recruiting

Phase 1/2 Study of CR-001 Safety and Dose Finding in Adults with Locally Advanced or Metastatic Solid Tumors

InvestigationalNo placebo
Countries:SpainSpain
  • Participants:18–64 years · 65+ years
Countries:SpainSpain
  • Participants:18–64 years · 65+ years
  • Substances:Gemcitabine
  • Sponsor:Orion Corporation

Neoplasm

Recruiting

EIK1005 Alone and with Pembrolizumab for Advanced Solid Tumors in Patients with MSI-H or dMMR Tumors

Registered drugNo placebo
Countries:SpainSpain
  • Participants:18–64 years · 65+ years
  • Substances:Pembrolizumab
  • Sponsor:Eikon Therapeutics Inc.

Neoplasm

Recruiting

A study of RPTR-1-201 and pembrolizumab in patients with advanced solid tumors

Registered drugNo placebo
Countries:SpainSpain
  • Participants:18–64 years · 65+ years
  • Substances:Pembrolizumab
  • Sponsor:Repertoire Immune Medicines Inc.

A study of YL201 and atezolizumab for patients with advanced solid tumors

Registered drugNo placebo
Countries:SpainSpain
  • Participants:18–64 years · 65+ years
  • Substances:Atezolizumab
  • Sponsor:Medilink Therapeutics (Suzhou) Co. Ltd.
Is this your site?

Join our network of research sites

Get verified: confirm your contact details and recruitment status with us, appear first on the pages of your trials and receive patient requests directly.

See the offer for sites
Clinical Trials Concierge

Prefer not to search? Our Concierge searches the trials for you.

Tell us about your condition – we search every trial in Europe and connect you with the right site.